Among the “really well-powered, rigorously designed clinical trials” NIH is set to launch for COVID-19 is the ACTIV-four umbrella of antithrombotic research, with at least 3 adaptive platform clinical trials on security and effectiveness of numerous agents for adults. (STAT, NIH)
Heparin, as properly as an analogue without the need of anticoagulant properties, worked on par with remdesivir in inhibiting SARS-CoV-two infection in mammalian cells — apparently acting as a decoy for the virus to attach to alternatively of the ACE2 receptor on cells. (Cell Discovery)
Dexmedetomidine began at cardiac surgery anesthesia induction and continued for 24 hours afterward did not reduce postoperative atrial arrhythmias or delirium in the DECADE trial. (The Lancet)
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
